Vaccine, pneumococcal


Concise Prescribing Info
Indications/Uses
Active immunisation against pneumococcal disease.
Dosage/Direction for Use
Adult : IM As 13- or 23-valent conjugate vaccine: Primary immunisation: 0.5 mL as a single dose. SC As 23-valent conjugate vaccine: Primary immunisation: 0.5 mL as a single dose.
Dosage Details
Intramuscular
Active immunisation against pneumococcal disease
Adult: As 13-valent conjugate vaccine: Primary immunisation: 0.5 mL as a single dose.
Child: As 10- or 13-valent conjugate vaccine: Primary immunisation: 6 weeks to 5 years 3 doses of 0.5 mL given at least 1 month apart. Booster dose given between 12-15 months of age or at least 6 months after the last dose. Alternatively, 2 doses of 0.5 mL given at 6 weeks of age, then 2nd dose given 2 months later. Booster dose given between 12-15 months of age or at least 6 months after the last dose. In unvaccinated infants and children: 7-11 months 2 doses of 0.5 mL give at least 1 month apart. 3rd dose at 2 years of age; 2-23 months 2 doses of 0.5 mL give at least 2 months apart; 2-17 years Same as adult dose.

Intramuscular, Subcutaneous
Active immunisation against pneumococcal disease
Adult: As 23-valent conjugate vaccine: Primary immunisation: 0.5 mL as a single dose via IM or SC inj. Revaccination may be considered for persons with increased risk.
Child: As 23-valent conjugate vaccine: ≥2 years Same as adult dose.
Contraindications
Hypersensitivity.
Special Precautions
Patient with history of coagulation disorders (including thrombocytopenia), severe CV and pulmonary dysfunction, immunosuppression. Postpone vaccination in patients with moderate or severe acute febrile illness. Not indicated for treatment of pneumococcal infections. Renal and hepatic impairment. Children. Pregnancy and lactation.
Adverse Reactions
Significant: Inj site reactions (e.g. pain, redness, bruising, swelling, induration); hypersensitivity reactions, fever, syncope, headache, rash.
General disorders and administration site conditions: Irritability, fatigue.
Metabolism and nutrition disorders: Decreased appetite.
Musculoskeletal and connective tissue disorders: Chills, myalgia, arthralgia.
Psychiatric disorders: Somnolence, insomnia.
IM/Parenteral/SC: C
Patient Counseling Information
This drug may cause syncope, if affected, do not drive or operate machinery.
MonitoringParameters
Monitor for hypersensitivity reactions 15 minutes after administration. Antibiotic prophylaxis should be continued after vaccination.
Drug Interactions
Increased risk of bleeding with anticoagulants. Decreased immune response with immunosuppressive therapies (e.g. high dose corticosteroids).
Action
Description: Pneumococcal vaccine, an inactive bacterial vaccine, contains purified capsular polysaccharides of pneumococcal serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F that promotes active immunisation against diseases caused by these S. pneumoniae serotypes.
Onset: Immunity: Approx 2-3 weeks.
Duration: At least 5 years.
Storage
Store between 2-8°C. Do not freeze. Protect from light. Any unused portions should be disposed of in accordance with local requirements.
ATC Classification
J07AL - Pneumococcal vaccines ; Used for active immunizations.
References
Anon. Penumococcal Polysaccharide Vaccine (23-Valent). Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 10/07/2018.

Anon. Pneumococcal Conjugate Vaccine (10-Valent). Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 10/07/2018.

Anon. Pneumococcal Conjugate Vaccine (13-Valent). Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 10/07/2018.

Buckingham R (ed). Pneumococcal Vaccines. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 10/07/2018.

Joint Formulary Committee. Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed). British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 10/07/2018.

Pneumovax 23 Injection (Merck Sharp & Dohme Corp.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 10/07/2018.

Disclaimer: This information is independently developed by MIMS based on Vaccine, pneumococcal from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
  • Pneumo 23
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in